Pharma Research Uses Luxid® Software Solution to Generate and Validate Hypotheses in Drug Discovery and Development Processes

New York, NY, USA – September 29, 2008 - The strong emphasis that TEMIS, the leading provider of Text Analytics solutions, has put on the Life Science market since many years has led to another important licensing agreement: Merck KGaA decided to deploy TEMIS to support hypothesis generation and validation services of their Research Knowledge Management department.

The generation and validation of hypotheses that drive drug discovery involves constant scanning of massive volumes of scientific literature, patents, adverse event reports, company reports, news, patient generated content, etc. While the intellectual capacity of experts in digesting and understanding this information is still vital today, the creative thinking process can benefit a lot from automatic support of appropriate software solutions. Such a solution needs to be capable of detecting the specific concepts of the Life Sciences domain such as biological and chemical entities or diseases as well as their respective relations to one another. It also requires easy customization capabilities, industrial strength and high performance. The result of such an analysis must be made accessible through an intuitive interface in order to allow for the efficient detection of relevant pieces of information, and also for in-depth data mining.

“The fact that the team of Merck KGaA with the rare and pronounced double competence in both pharma research and natural language processing decides to go with TEMIS in order to satisfy their text mining needs is a valuable acknowledgement of the quality of our software solution”, says Stefan Geißler, Managing Director of TEMIS Deutschland GmbH. “Merck KGaA is a determined and creative client and it is evident that the cooperation will be equally fruitful for both partners.”